Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients

International Journal of Clinical Practice

Volumn 60, Issue 4, 2006, Pages 415-421

  Tsagaraki, V ^a   Amfilochiou, A ^b   Markantonis, Sophia L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

Author keywords

2 agonists; Anticholinergics; COPD; Tachyphylaxis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALMETEROL; THEOPHYLLINE;

AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TACHYPHYLAXIS; VITAL CAPACITY;

ADRENERGIC BETA-AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TACHYPHYLAXIS;

EID: 33645061248     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00849.x     Document Type: Article

References (28)

1. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279-85.
2. Conolly ME, Davies DS, Dollery CT et al. Resistance to beta-adrenoceptors stimulants. Br J Clin Pharmacol 1971; 43: 389-402.
3. Boulet LP. Long versus short term β2-agonists. Implications for asthma management. Drugs 1994; 47: 207-22.
4. Malo JL, Ghezzo H, Trudeau C et al. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 567-74.
5. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571-5.
6. Boulet LP, Cartier A, Milot J et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: Influence of inhaled corticosteroids. Eur Respir J 1998; 11: 1091-7.
7. Nelson JA, Strauss L, Skowronski M et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141-6.
8. Harvey JE, Tattersfield AE. Airway response to salbutamol inhalations in normal, atopic and asthmatic subjects. Thorax 1982; 37: 280-7.
9. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156-60.
10. Friedman M, Serby CW, Menjoge SS et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-41.
11. American Thoracic Society. Standardization of Spirometry - 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107-36.
12. Tashkin DP, Conolly ME, Deutch RI et al. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis 1982; 125: 185-93.
13. Holgate ST, Baldwin CJ, Tattersfield AE. Beta adrenergic agonists resistance in normal human airways. Lancet 1975; 2: 375-7.
14. Thiadens HA, De Bock GH, Van Houwelingen JC et al. Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV(1) in primary care patients presenting with a persistent cough? Thorax 1999; 54: 1055-60.
15. Grove A, Lipworth BJ, Reid P et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-93.
16. Rennard SI, Serby CW, Ghafouri M et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62-70.
17. Georgopoulos D, Wong D, Anthonisen NR. Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease. Chest 1990; 97: 280-4.
18. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
19. Donohue JF, Van Noord IA, Bateman E et al. A 6 month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
20. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97: 1014-20.
21. Cheung D, Timmers MC, Zwinderman AH et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-203.
22. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: A novel, long-acting beta 2-agonist. Ann Pharmacother 1993; 27: 1478-87.
23. Ramage L, Lipworth BJ, Ingram CG et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-8.
24. Bhagat R, Kalra S, Swystun VA et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-9.
25. Karla S, Swystun VA, Bhagat R et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-6.
26. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 1999; 80: 31-4.
27. Sears MR. Asthma treatment: Inhaled beta-agonists. Can Respir J 1998; 5 (Suppl. A): 54-9A.
28. Dottorini ML, Tantucci C, Peccini F et al. Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol. Int J Clin Pharmacol Ther 1996; 34: 438-43.